Paper Details

  1. Home
  2. Paper Details

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

Author: AhmadAzura Rozila, BerghoffKarin, BrunsRolf, ChengYing, HsiaTe-Chun, JohneAndreas, KimDong-Wan, LiamChong Kin, LuShun, ShinSang Won, SooRoss Andrew, WuYi-Long, YangJames Chih-Hsin, ZhangYiping, ZhaoJun, ZhouJianying

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tepotinib plus gefitinib demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in patients with MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC) who had progressed on EGFR inhibitors. In a subgroup analysis of 19 patients, median PFS was 4.9 months vs 4.4 months and median OS was 19.9 months vs 2.8 months for tepotinib plus gefitinib vs chemotherapy, respectively. These results suggest tepotinib plus gefitinib as a promising therapeutic option for this specific patient population.
Paper Details　
Original Abstract of the Article :
PURPOSE: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). PATIENTS AND METHODS: Adults with advanced/metastatic EGFR-mutant NSCLC, ac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183805/

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Lung Cancer Treatment: Tepotinib Plus Gefitinib for EGFR-Mutant NSCLC

Lung cancer, a daunting foe, often requires complex and multifaceted treatment strategies. This study, like a beacon of hope in the vast desert of lung cancer research, explores the potential of combining tepotinib, a selective MET inhibitor, with gefitinib, an EGFR inhibitor, to target specific genetic mutations in EGFR-mutant non-small cell lung cancer (NSCLC).

Tepotinib Plus Gefitinib: A Promising Combination Therapy

The study's findings, like a refreshing oasis in the desert of lung cancer treatment, suggest that combining tepotinib with gefitinib may offer a significant improvement in progression-free survival (PFS) and overall survival (OS) for patients with EGFR-mutant NSCLC who have developed resistance to EGFR inhibitors due to MET amplification. This innovative combination therapy is like finding a new path through the desert, offering a potential route towards better outcomes for patients.

Navigating Lung Cancer Treatment: A Personalized Approach

The study emphasizes the importance of a personalized approach to lung cancer treatment, tailoring therapies to individual genetic profiles. It's like selecting the most appropriate camel for a particular desert journey, ensuring a safe and effective expedition. The authors encourage further research to optimize the use of tepotinib and gefitinib in combination therapy and explore its potential for other lung cancer subtypes.

Dr. Camel's Conclusion

This research offers a glimmer of hope in the fight against lung cancer, demonstrating the power of targeted therapies and personalized medicine. It's a testament to the ongoing pursuit of new and innovative approaches in the vast and challenging desert of cancer research.
Date :
  1. Date Completed 2023-05-16
  2. Date Revised 2023-05-18
Further Info :

Pubmed ID

36971777

DOI: Digital Object Identifier

PMC10183805

Related Literature

Article Analysis
・Effects of tepotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.